Benjamin Edwards Inc. Has $50.83 Million Stock Position in Stryker Co. (NYSE:SYK)

Benjamin Edwards Inc. increased its holdings in Stryker Co. (NYSE:SYK) by 2,140.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,676 shares of the medical technology company’s stock after acquiring an additional 134,396 shares during the period. Stryker comprises 0.7% of Benjamin Edwards Inc.’s investment portfolio, making the stock its 23rd biggest holding. Benjamin Edwards Inc.’s holdings in Stryker were worth $50,833,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Centennial Bank AR boosted its position in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in Stryker during the 3rd quarter worth $36,000. HBW Advisory Services LLC bought a new stake in shares of Stryker in the 3rd quarter worth $42,000. Hara Capital LLC purchased a new stake in shares of Stryker in the third quarter valued at about $42,000. Finally, Grove Bank & Trust lifted its position in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after purchasing an additional 56 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wells Fargo & Company increased their price objective on shares of Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. BTIG Research increased their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Canaccord Genuity Group lifted their target price on Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Evercore ISI boosted their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at $3,715,540. This represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,781 shares of company stock valued at $24,612,275. Company insiders own 5.50% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $392.15 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a market capitalization of $149.50 billion, a price-to-earnings ratio of 42.03, a price-to-earnings-growth ratio of 2.96 and a beta of 0.94. Stryker Co. has a 52-week low of $285.79 and a 52-week high of $398.20. The stock’s 50-day simple moving average is $368.51 and its 200 day simple moving average is $351.74.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the previous year, the company earned $2.46 earnings per share. Stryker’s revenue for the quarter was up 11.9% on a year-over-year basis. Research analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.